While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

Obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) has filed for a $100M initial public offering. Aardvark (NASDAQ:AARD) didn't disclose any terms in its SEC filing, but indicated in its ...

GREEN BAY − After seven years, a popular downtown winery and lounge will close this month. Aardvark Wine Lounge, 304 Pine St., in Green Bay opened Jan. 6, 2017 and will officially close on Feb ...

Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emerging player in the weight ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The Machine Shed in Lake Elmo, an east metro comfort food spot for more than two decades, has closed. Heart of America Group, the restaurant's owner, is preparing for an extensive remodel of the space ...

Aardvark may be close behind with a medicine codenamed ARD-101. The company’s drug acts on certain types of so-called bitter taste receptors which, as their name suggests, convey acrid flavor from the ...